Sudden death forces Sophiris to halt followup therapy in prostate cancer study — shares crushed
Small-cap biotech Sophiris $SPHS has hit the brakes on its dosing schedule for patients in its Phase IIb prostate cancer study after one of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
